These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 191185)

  • 21. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer.
    Beex L; Pieters G; Smals A; Koenders A; Benraad T; Kloppenborg P
    Cancer Treat Rep; 1981; 65(3-4):179-85. PubMed ID: 7237448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of breast cancer.
    Cohen IA; Keller JH; Abate MA
    Clin Pharm; 1982; 1(6):515-29. PubMed ID: 6192963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
    Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
    Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A case of advanced breast cancer with multiple organ metastases successfully treated by tamoxifen].
    Shiba E; Kobayashi T; Takeda T; Miya A; Kawano I; Takai S; Mori T
    Gan To Kagaku Ryoho; 1992 Nov; 19(13):2255-8. PubMed ID: 1444494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic value of nafoxidine hydrochloride in the treatment of advanced carcinoma of the human breast.
    Sasaki GH; Leung BS; Fletcher WS
    Surg Gynecol Obstet; 1976 Apr; 142(4):560-4. PubMed ID: 1257870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer.
    Budd GT; Adamson PC; Gupta M; Homayoun P; Sandstrom SK; Murphy RF; McLain D; Tuason L; Peereboom D; Bukowski RM; Ganapathi R
    Clin Cancer Res; 1998 Mar; 4(3):635-42. PubMed ID: 9533531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
    Miller AA; Lipton A; Henderson IC; Navari R; Mulagha MT; Cooper J
    Cancer; 1996 Aug; 78(4):789-93. PubMed ID: 8756373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer.
    Kiang DT; Frenning DH; Goldman AI; Ascensao VF; Kennedy BJ
    N Engl J Med; 1978 Dec; 299(24):1330-4. PubMed ID: 714108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The surgical implications of estrophile protein estimations in carcinoma of the breast.
    Walt AJ; Singhakowinta A; Brooks SC; Cortez A
    Surgery; 1976 Oct; 80(4):506-12. PubMed ID: 184556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiprolactinemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with LHRH-analogue, tamoxifen and the long-acting antiprolactinemic drug cabergoline.
    Lissoni P; Vaghi M; Villa S; Bodraska A; Cerizza L; Tancini G; Gardani GS
    Anticancer Res; 2003; 23(1B):733-6. PubMed ID: 12680176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prediction of hormonal dependency of mammary cancer.
    Block GE; Jensen EV; Polley TZ
    Ann Surg; 1975 Sep; 182(3):342-52. PubMed ID: 169754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Results of hormone therapy with aminoglutethimide (Rodazol) in postmenopausal metastatic breast cancer].
    Schmidt UM; Brockmann B; Geschke E
    Geburtshilfe Frauenheilkd; 1991 Apr; 51(4):276-9. PubMed ID: 1713564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The in vivo uptake of tritiated estradiol in carcinoma of the breast.
    Viladiu P
    Surg Gynecol Obstet; 1975 Apr; 140(4):544-6. PubMed ID: 165580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tamoxifen (antiestrogen) therapy in advanced breast cancer.
    Kiang DT; Kennedy BJ
    Ann Intern Med; 1977 Dec; 87(6):687-90. PubMed ID: 931204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hormone therapy of breast cancer].
    Maass H
    Med Welt; 1976 May; 27(21):1047-51. PubMed ID: 180375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association.
    Muss HB; Wells HB; Paschold EH; Black WR; Cooper MR; Capizzi RL; Christian R; Cruz JM; Jackson DV; Powell BL
    J Clin Oncol; 1988 Jul; 6(7):1098-106. PubMed ID: 3292710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Rebound regression after additional hormonal treatment with ethinyl oestradiol of metastasising carcinoma of the breast in females: frequency and clinical significance (author's transl)].
    Quednau D; Garbrecht M; Stolzenbach G; Nowakowski H
    Dtsch Med Wochenschr; 1978 Dec; 103(51):2029-32. PubMed ID: 729476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.